Weekly Analysts’ Ratings Changes for IQVIA (IQV)

IQVIA (NYSE: IQV) has recently received a number of price target changes and ratings updates:

• 10/23/2024 – IQVIA had its price target lowered by analysts at JPMorgan Chase & Co. from $288.00 to $279.00. They now have an “overweight” rating on the stock.
• 10/22/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 10/15/2024 – IQVIA had its price target lowered by analysts at Barclays PLC from $275.00 to $260.00. They now have an “overweight” rating on the stock.
• 10/14/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/14/2024 – IQVIA had its price target lowered by analysts at Truist Financial Co. from $300.00 to $286.00. They now have a “buy” rating on the stock.
• 10/14/2024 – IQVIA is now covered by analysts at Redburn Atlantic. They set a “buy” rating and a $276.00 price target on the stock.
• 10/8/2024 – IQVIA had its price target lowered by analysts at Evercore ISI from $270.00 to $265.00. They now have an “outperform” rating on the stock.
• 9/27/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/20/2024 – IQVIA had its price target raised by analysts at Robert W. Baird from $251.00 to $256.00. They now have a “neutral” rating on the stock.
• 9/5/2024 – IQVIA was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 9/4/2024 – IQVIA is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $275.00 price target on the stock.
• 8/27/2024 – IQVIA was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.

IQVIA Price Performance

IQVIA stock opened at $228.31 on Thursday. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a market cap of $41.62 billion, a P/E ratio of 29.65, a PEG ratio of 2.26 and a beta of 1.49. The company has a 50-day moving average price of $238.71 and a 200 day moving average price of $230.92. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. During the same quarter last year, the firm posted $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Park Place Capital Corp acquired a new stake in IQVIA during the third quarter worth approximately $28,000. Versant Capital Management Inc raised its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Riverview Trust Co acquired a new stake in IQVIA during the first quarter worth approximately $32,000. Opal Wealth Advisors LLC acquired a new stake in IQVIA during the second quarter worth approximately $27,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in IQVIA during the second quarter worth approximately $29,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.